TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an update.
Chimeric Therapeutics Limited responded to an ASX query regarding the ADVENT-AML clinical trial results. The company disclosed that no dose-limiting toxicities were observed, and CORE-NK cells persisted in patients’ blood. Notably, 57% of high-risk frontline subjects showed clinical responses, with two new complete responses in AML. This information, although not initially disclosed, is considered to have a potential material impact on the company’s securities when combined with additional new data.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is a biotechnology company focused on developing innovative therapies for cancer treatment. The company is involved in clinical trials, such as the ADVENT-AML trial, which utilizes its CORE-NK technology, primarily funded by MD Anderson Cancer Center.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.93M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.